Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | PRGN-2009 |
Synonyms | |
Therapy Description |
PRGN-2009 consists of a gorilla adenovirus (GAd) that encodes agonistic HPV E6 and E7 epitopes, which potentially enhances antitumor immune response against HPV-positive tumors and reduces tumor growth (J Immunol 2020, 204 (1 Supplement) 91.6). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
PRGN-2009 | PRGN2009|PRGN 2009 | PRGN-2009 consists of a gorilla adenovirus (GAd) that encodes agonistic HPV E6 and E7 epitopes, which potentially enhances antitumor immune response against HPV-positive tumors and reduces tumor growth (J Immunol 2020, 204 (1 Supplement) 91.6). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04432597 | Phase Ib/II | PRGN-2009 Bintrafusp alfa + PRGN-2009 | HPV Vaccine PRGN-2009 Alone or in Combination With Anti-PDL1/TGF-Beta Trap (M7824) in Subjects With HPV Associated Cancers | Active, not recruiting | USA | 0 |